Elevai Labs
ELAB
2 hedge funds and large institutions have $7.16K invested in Elevai Labs in 2025 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.
76% more capital invested
Capital invested by funds: $4.06K → $7.16K (+$3.1K)
0% more funds holding
Funds holding: 2 → 2 (0)
0% more ownership
Funds ownership: 0% → 0% (+0%)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$13.1K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$8.31K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$973 |
ELAB Hedge Fund Activity: Q4 2025 in Review
2 of the 8,266 institutional investors tracked by Wall St. Rank reported a position in Elevai Labs (ELAB) for Q4 2025, worth a combined $7.16K — up 76% from $4.06K a quarter earlier.
Fund positioning in ELAB was balanced in Q4 2025: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was Tower Research Capital (TRC), adding an estimated $13.1K. The largest seller was Citigroup, exiting entirely with an estimated $973 sold.
- 2 institutional investors held Elevai Labs (ELAB) as of Q4 2025, unchanged from Q3 2025.
- Funds reported $7.16K of Elevai Labs stock for Q4 2025, up 76% quarter-over-quarter.
- 1 fund opened new Elevai Labs positions in Q4 2025 and 1 closed out, a net change of 0 holders.
- The largest Elevai Labs buyer in Q4 2025 was Tower Research Capital (TRC), an estimated $13.1K added.
- The largest Elevai Labs seller in Q4 2025 was Citigroup, an estimated $973 sold.
Based on aggregated 13F filings for Q4 2025.